Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Trial of Leflunomide in African-American and European-American Patients With High-Risk Smoldering Multiple Myeloma

NCT05014646 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT05014646
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05014646 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Trial of Leflunomide in African-American and European-American Patients With High-Risk Smoldering Multiple Myeloma
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 7, 2022
Completion date
January 16, 2027
Enrollment
27 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

smoldering plasma cell myeloma